Improving diagnostic molecular tests to monitor urothelial carcinoma recurrence

Laura Maria Krabbe, Solomon L. Woldu, Shahrokh F. Shariat, Yair Lotan

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Introduction: The high recurrence rates associated with non-muscle invasive bladder cancer require close surveillance with cystoscopy, an invasive and expensive procedure with risk of missing cancer. Finding an accurate urinary biomarker that can detect recurrent disease would represent a significant advancement in management. Areas covered: This review summarizes the commercially-available urinary biomarkers including cytology, UroVysion, BTA, NMP22, uCyt+, and Cxbladder assays. Additionally, we review recent investigational urinary biomarkers that hold promise in bladder cancer surveillance. Expert commentary: The quest for a reliable urinary biomarker for bladder cancer is decades-old and seems intuitive given the direct contact of urine with malignant urothelium. Beyond urine cytology, there are many commercially-available products approved for surveillance. However, none of the assays are routinely used due to lack of sensitivity and/or specificity. As such, emerging technologies, in particular the ‘–omic’ technologies have resulted in a proliferation of promising reports on novel biomarkers in recent literature.

Original languageEnglish (US)
Pages (from-to)1189-1199
Number of pages11
JournalExpert Review of Molecular Diagnostics
Volume16
Issue number11
DOIs
StatePublished - Nov 1 2016

Fingerprint

Routine Diagnostic Tests
Biomarkers
Carcinoma
Recurrence
Urinary Bladder Neoplasms
Cell Biology
Urine
Technology
Urothelium
Cystoscopy
Sensitivity and Specificity
Neoplasms

Keywords

  • Bladder cancer
  • follow-up
  • molecular biomarker
  • non-muscle invasive
  • surveillance
  • transitional cell carcinoma
  • urothelial carcinoma

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Improving diagnostic molecular tests to monitor urothelial carcinoma recurrence. / Krabbe, Laura Maria; Woldu, Solomon L.; Shariat, Shahrokh F.; Lotan, Yair.

In: Expert Review of Molecular Diagnostics, Vol. 16, No. 11, 01.11.2016, p. 1189-1199.

Research output: Contribution to journalReview article

Krabbe, Laura Maria ; Woldu, Solomon L. ; Shariat, Shahrokh F. ; Lotan, Yair. / Improving diagnostic molecular tests to monitor urothelial carcinoma recurrence. In: Expert Review of Molecular Diagnostics. 2016 ; Vol. 16, No. 11. pp. 1189-1199.
@article{fc8ff2c9319a4a6e8b1738cad19ebe98,
title = "Improving diagnostic molecular tests to monitor urothelial carcinoma recurrence",
abstract = "Introduction: The high recurrence rates associated with non-muscle invasive bladder cancer require close surveillance with cystoscopy, an invasive and expensive procedure with risk of missing cancer. Finding an accurate urinary biomarker that can detect recurrent disease would represent a significant advancement in management. Areas covered: This review summarizes the commercially-available urinary biomarkers including cytology, UroVysion, BTA, NMP22, uCyt+, and Cxbladder assays. Additionally, we review recent investigational urinary biomarkers that hold promise in bladder cancer surveillance. Expert commentary: The quest for a reliable urinary biomarker for bladder cancer is decades-old and seems intuitive given the direct contact of urine with malignant urothelium. Beyond urine cytology, there are many commercially-available products approved for surveillance. However, none of the assays are routinely used due to lack of sensitivity and/or specificity. As such, emerging technologies, in particular the ‘–omic’ technologies have resulted in a proliferation of promising reports on novel biomarkers in recent literature.",
keywords = "Bladder cancer, follow-up, molecular biomarker, non-muscle invasive, surveillance, transitional cell carcinoma, urothelial carcinoma",
author = "Krabbe, {Laura Maria} and Woldu, {Solomon L.} and Shariat, {Shahrokh F.} and Yair Lotan",
year = "2016",
month = "11",
day = "1",
doi = "10.1080/14737159.2016.1244006",
language = "English (US)",
volume = "16",
pages = "1189--1199",
journal = "Expert Review of Molecular Diagnostics",
issn = "1473-7159",
publisher = "Expert Reviews Ltd.",
number = "11",

}

TY - JOUR

T1 - Improving diagnostic molecular tests to monitor urothelial carcinoma recurrence

AU - Krabbe, Laura Maria

AU - Woldu, Solomon L.

AU - Shariat, Shahrokh F.

AU - Lotan, Yair

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Introduction: The high recurrence rates associated with non-muscle invasive bladder cancer require close surveillance with cystoscopy, an invasive and expensive procedure with risk of missing cancer. Finding an accurate urinary biomarker that can detect recurrent disease would represent a significant advancement in management. Areas covered: This review summarizes the commercially-available urinary biomarkers including cytology, UroVysion, BTA, NMP22, uCyt+, and Cxbladder assays. Additionally, we review recent investigational urinary biomarkers that hold promise in bladder cancer surveillance. Expert commentary: The quest for a reliable urinary biomarker for bladder cancer is decades-old and seems intuitive given the direct contact of urine with malignant urothelium. Beyond urine cytology, there are many commercially-available products approved for surveillance. However, none of the assays are routinely used due to lack of sensitivity and/or specificity. As such, emerging technologies, in particular the ‘–omic’ technologies have resulted in a proliferation of promising reports on novel biomarkers in recent literature.

AB - Introduction: The high recurrence rates associated with non-muscle invasive bladder cancer require close surveillance with cystoscopy, an invasive and expensive procedure with risk of missing cancer. Finding an accurate urinary biomarker that can detect recurrent disease would represent a significant advancement in management. Areas covered: This review summarizes the commercially-available urinary biomarkers including cytology, UroVysion, BTA, NMP22, uCyt+, and Cxbladder assays. Additionally, we review recent investigational urinary biomarkers that hold promise in bladder cancer surveillance. Expert commentary: The quest for a reliable urinary biomarker for bladder cancer is decades-old and seems intuitive given the direct contact of urine with malignant urothelium. Beyond urine cytology, there are many commercially-available products approved for surveillance. However, none of the assays are routinely used due to lack of sensitivity and/or specificity. As such, emerging technologies, in particular the ‘–omic’ technologies have resulted in a proliferation of promising reports on novel biomarkers in recent literature.

KW - Bladder cancer

KW - follow-up

KW - molecular biomarker

KW - non-muscle invasive

KW - surveillance

KW - transitional cell carcinoma

KW - urothelial carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84992730290&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992730290&partnerID=8YFLogxK

U2 - 10.1080/14737159.2016.1244006

DO - 10.1080/14737159.2016.1244006

M3 - Review article

C2 - 27696932

AN - SCOPUS:84992730290

VL - 16

SP - 1189

EP - 1199

JO - Expert Review of Molecular Diagnostics

JF - Expert Review of Molecular Diagnostics

SN - 1473-7159

IS - 11

ER -